# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2024 Earnings Results

**Report date:** 2024-10-31 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2024

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 9.17%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $12.46 | N/A | +23.89% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Defensive

Management expressed caution regarding market conditions and highlighted their commitment to research and development. They did not provide specific guidance for future quarters.

**Key quotes:**

> Management noted ongoing challenges in the market.

> They emphasized a focus on innovation despite current pressures.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Regeneron's earnings report showed a strong EPS performance, exceeding expectations significantly. However, the stock fell by 9.17% in reaction, likely due to the lack of revenue data and cautious management commentary about market challenges. Investors may be concerned about the company's future performance without clear guidance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2024_